Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Prevention and Screening in BRCA Mutation Carriers and Other Breast/Ovarian Hereditary Cancer Syndromes: ESMO Clinical Practice Guidelines

Published in 2016 – Ann Oncol (2016) 27 (suppl 5): v103-v110 
Authors: S. Paluch-Shimon, F. Cardoso, C. Sessa, J. Balmana, M. J. Cardoso, F. Gilbert and E. Senkus

These guidelines focus on cancer prevention and screening among individuals known to harbour a pathogenic BRCA1/2 mutation. The presence of a BRCA1 or BRCA2 mutation accounts for the majority of hereditary breast and ovarian cancer syndromes. Genetic susceptibility to breast or ovarian cancer might also be associated with mutations in other genes, some of which are associated with known hereditary cancer syndromes. With other genes, the cancer risk association such as is still under research or clinical validation. For initial risk assessment and the decision when to perform genetic counselling and testing, the reader is referred to the recently updated National Comprehensive Cancer Network guidelines on genetic/familial high-risk assessment and The National Institute for Health and Clinical Excellence guidelines.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.